ESMO Highlights

touchONCOLOGY spoke to Prof Misako Nagasaka (University of California Irvine, Detroit, MI, USA) to discuss her presentation at the European Lung Cancer Summit 2022, providing the results of the TRUST-II study, a global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumours. Questions       What is taletrectinib […]

The CASPIAN study evaluated the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC. touchONCOLOGY spoke to Niels Reinmuth (Munich, Germany) to discuss the characteristics of long-term survivors in the CASPIAN study. Clinical Trial Identification: NCT03043872 Questions       What did the CASPIAN study teach us about the efficacy and safety of […]

There is still extensive ongoing research, however CAR-T technology for lung cancer is providing much promise but many challenges. touchONCOLOGY spoke to Dr Prasad S Adusumilli (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) to discuss the potential of CAR-T therapy in lung cancer and the recent breakthroughs in this area.  Questions       […]

“The tissue is the issue” was a strong theme of the 2013 CAP/IASLC/AMP guidelines. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Summit 2022, providing an update on the current state of personalized medicine and molecular testing in lung […]

Molecular testing is important to selecting patients with advanced non-small cell lung cancer (NSCLC) who may benefit from targeted therapy or immunotherapy. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Summit 2022, providing an update on the current state of […]

Non-small cell lung cancer (NSCLC) shows the success of personalized medicine in treating solid tumors. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Summit 2022, providing an update on the current state of personalized medicine and molecular testing in lung […]

Biomarker testing is important for determining the the best treatment for patients newly diagnosed with NSCLC. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Summit 2022, providing an update on the current state of personalized medicine and molecular testing in […]

touchONCOLOGY spoke to Dr Lizza Hendriks (Maastricht University, The Netherlands) to discuss her presentation at the European Lung Cancer Summit 2022, providing an update on the use of immunotherapy for the treatment for non-oncogene addicted non-small cell lung cancer with brain metastases.  Questions       Could you give us a brief overview of current […]

touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part One click here. Questions 1. How did immune responses relate to cancer stage and disease status? (00:18-03:26) 2. What are the implications of […]